Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)

Starting soon · Phase 2

Conditions studied: Environmental Enteric Dysfunction

In brief

The goal of this clinical trial is to learn whether teduglutide, a medicine that helps the intestine heal, can improve environmental enteric dysfunction in undernourished women aged 18 to 35 years living in urban slums of Dhaka. Environmental enteric dysfunction is a long-lasting condition of the small intestine. It causes inflammation and poor absorption of nutrients. Many people with this condition do not have clear symptoms, but it can make undernutrition worse. At present, there is no proven treatment for this condition. The main questions this study aims to answer are: * Does taking teduglutide for 30 days improve damage to the small intestine, as seen on intestinal biopsy? * Does teduglutide improve blood and stool markers related to gut inflammation and nutrient absorption? Participants will: * Receive nutritional support at the start of the study * Undergo an upper gastrointestinal endoscopy to confirm environmental enteric dysfunction * Receive a daily injection of teduglutide under the skin for 30 days * Undergo repeat endoscopy and laboratory tests after treatment to assess changes in gut health The results of this study will help researchers understand whether teduglutide may be a useful treatment for environmental enteric dysfunction in undernourished adult women and will guide future, larger studies.

Key facts

Study ID

NCT07537686

Run by

International Centre for Diarrhoeal Disease Research, Bangladesh

People needed

55

Starts

2026-07-01

Expected to finish

2027-12-30

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Bangladeshi women, aged 18-35 years
• BMI between 16 kg/m2 to 18.5 kg/m2
• No antibiotics for 1 month
• Willing to sign the consent form
• Willing to receive food and multiple micronutrient supplementation for 2 months
• Willing to receive daily one-month sub-cutaneous GLP 2 analog, Teduglutide treatment
• Willing to undergo endoscopy and biopsy, twice, before and after intervention, if failed to respond to nutrition intervention and who did not have other chronic or acute diseases that may cause malnutrition
• Willing to provide biological samples during the study period of 4 months

You may not qualify if…

• Severe anemia (<8 g/dl), known case of TB, and other chronic diseases, including diabetes mellitus or any congenital disorder or deformity
• Pregnancy, lactation, drug abuse, known psychiatric disorders
• High clinical suspicion of cancer or other chronic or acute diseases that may cause malnutrition.
• Known allergy to any components of nutrition intervention or any GI polyp
• Ongoing episode of diarrhea, history of persistent diarrhea in the past month or history of acute diarrhea in the past 7 days

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.